Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Post by IBTryinIton May 13, 2011 9:58am

262 Views

Post# 18571633

TRADING

Looks like the market likes the news ... their proffits are up ...
Eniluracil Phase 2 Study ... study intends to enroll 140 patients at approximately 20 clinical sites in the United States and Russia in the next 12 to 14 months.
Rights Offering ... expired on March 29, 2011 proceeds received by the Company were approximately $2.5 million
Financial Update ... $2.5 million subscription receivable has working capital $7.1 million

Most everything is swinging in a positive direction ... this should help the SP and proceed in an upward trend

Bullboard Posts

The Market Online’s Weekly Cannabis Report – Nov. 22, 2024